http://hdl.handle.net/20.500.12283/68 Tue, 14 Apr 2026 21:49:41 GMT 2026-04-14T21:49:41Z http://hdl.handle.net/20.500.12283/2688 Community contribution to the control of Ebola outbreaks in Uganda, 2000-2022. Okware, Samuel Community contribution to the control of Ebola outbreaks in Uganda, 2000-2022 Research article Sat, 01 Oct 2022 00:00:00 GMT http://hdl.handle.net/20.500.12283/2688 2022-10-01T00:00:00Z http://hdl.handle.net/20.500.12283/2687 Strategies for the development of small molecule inhibitors of ebola viral infection. Pleško, Sebastian; Podlipnik, Črtomir The recent outbreak of Ebola viral disease (EVD) in West Africa reminded us that an effective anti-viral treatment still does not exist, despite the significant progress that has recently been made in understanding biology and pathology of this lethal disease. Currently, there are no approved vaccine and/or prophylactic medication for the treatment of EVD in the market. However, the serious pandemic potential of EVD mobilized research teams in the academy and the pharmaceutical industry in the effort to find an Ebola cure as fast as possible. In this chapter, we are giving the condensed review of different approaches and strategies in search of a drug against Ebola. We have been focusing on the review of the targets that could be used for in silico, in vitro, and/or in vivo drug design of compounds that interact with the targets in different phases of the Ebola virus life cycle. Keywords: small molecule inhibitors, Ebola virus, drug design, protein targets, structure and action Book chapter Fri, 01 Jan 2016 00:00:00 GMT http://hdl.handle.net/20.500.12283/2687 2016-01-01T00:00:00Z http://hdl.handle.net/20.500.12283/2686 Ebola virus’s glycoproteins and entry mechanism. Khataby, Khadija; Kasmi, Yassine; Hammou, Rahma Ait; Laasri, Fatima Ezzahra; Boughribil, Said; Ennaji, My Mustapha Ebola virus glycoprotein (GP) is the only protein that is expressed on the surface of the virus. The GP proteins play critical roles in the entry of virus into cell and in the evasion of the immune system. The GP gene transcript to membrane GP is constituted of two subunits GP1 and GP2,and the secretory GP (sGP). The main function of GP1/2 is to attach virus to target cell’s membrane, whereas sGP has multiple functions on Ebola pathogen‐ esis, such as inactivate neutrophils through CD16b causing lymphocyte apoptosis and vascular dysregulation. There are many studies that focused on better understanding the GP mechanism and aim at developing new antibodies and drugs such as VSV-EBOV, cAd3-EBO Z, rVSVN4CT1 VesiculoVax, ‘C-peptide’ based on the GP2 C-heptad repeat region (CHR) targeted to endosomes (Tat-Ebo) and MBX2270. In this chapter, we discuss the Ebola viral glycoproteins, genomic organization, synthesis, and their roles and functions. On the other hand, we treat the mechanisms of pathogenicity associated with Ebola GPs. Keywords: EBOLA, virus, glycoprotein (GP), entry, mechanism, pathogenesis, structure Book chapter Fri, 01 Jan 2016 00:00:00 GMT http://hdl.handle.net/20.500.12283/2686 2016-01-01T00:00:00Z http://hdl.handle.net/20.500.12283/2685 Roles of VP35, VP40 and VP24 proteins of ebola virus in pathogenic and replication mechanisms. Hammou, Rahma Ait; Kasmi, Yassine; Khataby, Khadija; Laasri, Fatima Ezzahra; Boughribil, Said; Ennaji, My Mustapha Ebola epidemic is a fatal disease due to Ebola virus belonging to Filoviridae; currently the viral evolution caused more than 50% of death worldwide. Among the eight proteins of ZEBOV, there are four structural proteins VP35, VP40, VP24, and NP, which have important functions in the intercellular pathogenic mechanisms. The multi‐functionali‐ ty of Ebola's viral proteins allows the virus to reduce its protein number to ensure its proper functioning and keeping the compact structure of the virus. Therefore, the aim of this chapter is to study the mechanism of replication and the roles of VP30, VP35, NP, and L in this process. We provide as well to highlight the influence of the virus on the immune system and on the VP24. Keywords: Ebola, VP35, VP40, VP24, pathogenic, replication, mechanisms, immune system Book chapter Fri, 01 Jan 2016 00:00:00 GMT http://hdl.handle.net/20.500.12283/2685 2016-01-01T00:00:00Z